Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Novavax Soars on Applying With WHO for Emergency Use of Covid Vaccine

Published 2021-09-23, 11:20 a/m
Updated 2021-09-23, 11:20 a/m
© Reuters

© Reuters

By Dhirendra Tripathi

Investing.com – Novavax stock (NASDAQ:NVAX) climbed 9% Thursday after the company applied with the World Health Organization for emergency approval to its much-delayed Covid-19 vaccine.

The application, filed jointly with its partner Serum Institute of India, follows the companies' previous regulatory submission to the Drugs Controller General of India.

The grant of emergency use license by the WHO is a prerequisite for exports to countries participating in the Covax facility, which was established to allocate and distribute vaccines equitably to participating countries.

Novavax and SII last month completed the submission of modules required by regulatory agencies in India, Indonesia and the Philippines for the initiation of review of the vaccine. SII is the world's largest vaccine manufacturer by capacity and also makes the Covid-19 shot developed by AstraZeneca. 

The submission of the application comes after several months of delay that has seen the likes of Pfizer (NYSE:PFE)-BioNTech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA), AstraZeneca (NASDAQ:AZN) and Gamaleya (Sputnik) race ahead in providing vaccines to millions of people worldwide.  

The vaccine, NVX-CoV2373, is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the coronavirus and comes at a time when the virus has mutated, leaving its Delta variant as the dominant strain in most countries of the world.

NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein.

Novavax' COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses given intramuscularly 21 days apart. The vaccine is stored at 2°- 8° Celsius, enabling the use of existing vaccine supply and cold chain channels.

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.